Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Japanese registry sheds light on how palmoplantar pustulosis is treated

NCT ID NCT04459507

Knowledge-focused Sponsor: Janssen Pharmaceutical K.K. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed registry study in Japan looked at how doctors treat palmoplantar pustulosis (PPP), a skin condition causing pus-filled blisters on hands and feet. Researchers collected data from 276 patients' medical records and clinic visits to understand which treatments are used and how long patients stay on them. No new treatment was tested; the goal was to describe real-world care patterns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

276 people

The number who actually took part.

Started

Mar 2021

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants observed in this study newly initiated/will be newly initiating a systemic therapy for their PPP/pustulotic arthro-osteitis (PAO) - either as their first systemic therapy or as a switch from, or an addition to a previous therapy, having had an inadequate response and/or intolerant to prior PPP/PAO therapy. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have a confirmed diagnosis of palmoplantar pustulosis (PPP) and/or pustulotic arthro-osteitis (PAO) in accordance with local clinical practice * Has previously been prescribed treatment for PPP/PAO * A decision has been made by the treating physician and the participant to commence treatment with a systemic PPP/PAO therapy, having been deemed to have an inadequate response to previous therapy (New users are defined as those participants to commence treatment on baseline visit date. Existing users are defined as those who commenced treatment prior to the baseline visit since 01 November 2019.) * Must sign a participation agreement/informed consent form allowing data collection and source data verification in accordance with local requirements Exclusion Criteria: * Are receiving, or have received within the past 3 months, anti-inflammatory or analgesic systemic therapy such as oral corticosteroid, disease modifying antirheumatic drug (DMARDs), non-steroidal anti-inflammatory drugs, opioids, phosphodiesterase 4 (PDE4) inhibitor, or biologics for any other indication (for example, psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and asthma) * Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the start of the study or the first data collection time point * Participation in an investigational study * Participation in another observational study for guselkumab (including a post marketing surveillance study) * If the only treatment they have received for PPP has been antibiotics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmoplantar pustulosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis SAPHO syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmoplantar pustulosis

Contacts and locations

Locations

  • Akita University Hospital

    Akita, 010-8543, Japan

  • Chikamori Hospital

    Kochi, 780-8522, Japan

  • Ehime University Hospital

    Tōon, 791-0295, Japan

  • Fujita Health University Hospital

    Toyoake, 470-1192, Japan

  • Fukushima Medical University Hospital

    Fukushima, 960 1295, Japan

  • Hamamatsu University Hospital

    Hamamatsu, 431-3192, Japan

  • Hiroshima City Asa Citizens Hospital

    Hiroshima, 731-0293, Japan

  • Hokkaido University Hospital

    Sapporo, 060-8648, Japan

  • JR Sapporo Hospital

    Hokkaido, 060-0033, Japan

  • Juntendo University Hospital

    Bunkyō City, 113 8431, Japan

  • Kansai Medical University Hospital

    Hirakata, 573 1191, Japan

  • Keio University Hospital

    Shinjuku-ku, 160-8582, Japan

  • Kindai University Hospital

    Ōsaka-sayama, 589-8511, Japan

  • Kita-harima Medical Center

    Hyōgo, 6751392, Japan

  • Kochi Medical School Hospital

    Kochi, 783-8505, Japan

  • Kurashiki Medical Center

    Kurashiki-shi, 710-8522, Japan

  • Kurume University Hospital

    Kurume, 830-0011, Japan

  • Kuwana City Medical Center

    Kuwana, 511 0061, Japan

  • Kyoto University Hospital

    Kyoto, 606-8507, Japan

  • Kyushu University Hospital

    Fukuoka, 812 8582, Japan

  • Nagoya City University Hospital

    Nagoya, 467 8602, Japan

  • National Hospital Organization Kyoto Medical Center

    Kyoto, 612-8555, Japan

  • Oita University Hospital

    Ōita, 879-5593, Japan

  • Okayama Saiseikai General Hospital

    Kita-ku, 700-8511, Japan

  • Okayama University Hospital

    Okayama, 700 8558, Japan

  • Sasebo Chuo Hospital

    Sasebo, 857 1195, Japan

  • Seiwakai Hiroshima Clinic

    Hiroshima, 733-0032, Japan

  • Shiga University of Medical Science Hospital

    Ōtsu, 520-2192, Japan

  • Shinshu University Hospital

    Matsumoto, 390 8621, Japan

  • St. Luke's International Hospital

    Tokyo, 104 8560, Japan

  • Takamatsu Red Cross Hospital

    Takamatsu, 760 0017, Japan

  • Teikyo University Hospital

    Itabashi Ku, 173 8606, Japan

  • The Hospital of Hyogo College of Medicine

    Nishinomiya, 663-8501, Japan

  • Toho University Medical Center, Ohashi Hospital

    Meguro-ku, 153-8515, Japan

  • Tohoku University Hospital

    Sendai, 980 8574, Japan

  • Tokyo Medical University Hachioji Medical Center

    Tokyo, 193-0998, Japan

  • Tokyo Medical University Hospital

    Tokyo, 160-0023, Japan

  • Yamanashi Prefectural Central Hospital

    Kofu, 400-8506, Japan

  • Yokosuka Kyosai Hospital

    Yokosuka, 238 8558, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.